Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Downgrades Threshold Pharmaceuticals (THLD) to Market Perform
December 7, 2015 9:38 AM ESTCowen downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Outperform to Market Perform.
Analyst Eric Schmidt commented, "Threshold and partner Merck KGaA announced that neither of evofosfamide's pivotal trials in pancreatic cancer or sarcoma met its primary OS endpoint. The results are disappointing, and... More
Threshold Pharma (THLD) Says Evofosfamide Studies Did Not Meet Primary Endpoints
December 7, 2015 6:18 AM ESTThreshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany.
In the Phase 3 MAESTRO study, patients with previously untreated, locally advanced unresectable or metastatic pancreatic... More
